BUSINESS

• Lilly’s Mounjaro Hits Japan Pharmacy Shelves, Mitsubishi as Distributor
  April 19, 2023

• Nobelpharma Sues Sawai over Nobelzin Patent in Japan
  April 19, 2023

• Over 40,000 Patients Given Xocova as of April 9: Shionogi
  April 18, 2023

• Rexulti Backed by FDA Advisors for Alzheimer’s Agitation: Otsuka/Lundbeck
  April 18, 2023

• Radicut Oral Form Now Available for ALS Patients in Japan: Mitsubishi Tanabe
  April 18, 2023

• BMS Seeks 3rd Line MM Use for Abecma in Japan
  April 18, 2023

• FDA OKs Nippon Shinyaku’s PII Plan for Exon 44-Directed DMD Drug
  April 17, 2023

• Upsher-Smith Launches Combigan Generic in US: Sawai
  April 17, 2023

• iPark Institute Takes Over Shonan iPark Operations from Takeda to Boost Neutrality, Collaborations
  April 14, 2023

• Sawai Moved Ahead with WPP Rate Hikes for Generics amid Tough Biz Environment
  April 14, 2023

• Chugai, TWOCELLS End Knee Chondrogenesis Cell Therapy Deal
  April 14, 2023

• Kaken Aborts ART-648 Program, Incurring 1.5 Billion Yen Impairment Loss
  April 14, 2023

• AstraZeneca Japan Grows 17% in 2022, Bags 12 Approvals; Up to 7 Filings Eyed for 2023
  April 14, 2023

• Axcelead to Expand Overseas Biz, Shoots for 130 Billion Yen Sales and 5,000-Plus Researchers
  April 13, 2023

• PET Imaging Agent Vizamyl Filed for Additional Use for AD Modifying Drug
  April 13, 2023

• Alexion Japan Recalling Ultomiris IV 300 mg/3 mL
  April 13, 2023

• Japan Lacks Talent, Ecosystem to Incubate Drug Seeds: Chugai Chair
  April 13, 2023

• Astellas, Kyoto University’s CiRA Extend iPS Cell Pact
  April 13, 2023

• Astellas Incurs 58 Billion Yen Impairment Loss on Sluggish Evrenzo, Other Factors
  April 12, 2023

• Sumitomo’s SaMD for Depression Gets Priority Review; Clinical Trial Launch Eyed within 3 Years
  April 12, 2023

ページ

• « 先頭
• ‹ Prev
• …
• 139
• 140
• 141
• 142
• 143
• 144
• 145
• 146
• 147
• …
• Next ›
• 最終 »